Role of Diagnostics in Managing HDV Infection
Diagnostics are central to the Hepatitis Delta Virus (HDV) Infection Market. Accurate identification of HDV RNA and antibodies is essential for proper patient management and monitoring treatment efficacy.
Serologic assays and molecular diagnostics have evolved to provide higher sensitivity and specificity. Point-of-care testing is also emerging, facilitating access in remote and resource-limited settings.
Early and reliable diagnostics enable timely therapeutic intervention, reducing disease progression and improving patient outcomes, thereby supporting overall market growth.